May 29 |
Cardiff Oncology to Present at the Jefferies Healthcare Conference
|
May 22 |
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
|
May 13 |
Cardiff Oncology to Present at Upcoming Investor Conferences in May
|
May 4 |
Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
|
May 3 |
Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript
|
May 2 |
Cardiff Oncology GAAP EPS of -$0.22 beats by $0.03, revenue of $0.2M beats by $0.14M
|
May 2 |
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
|
May 1 |
Cardiff Oncology Q1 2024 Earnings Preview
|
Apr 25 |
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
|
Apr 8 |
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
|